Redeye returns with a more in-depth take on the Q2 report. Despite challenging FX, we regard the quarter as strong and point to its impressive LTM sales development for US CERAMENT G. The share is bound to reignite momentum as additional revenue drivers kick in, namely increasing trauma sales and entry into the spine market with CERAMENT BVF. We make downward short- to medium-term sales revisions, notching down our base case.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/